Inventiva SA (id:10885 IVA)
2.46 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/28/2024 1:49:09 AM)
Exchange closed, opens in 7 hours 10 minutes
2.50 EUR (2.50%)
-4.65 EUR (-4.65%)
-4.65 EUR (-4.65%)
-25.45 EUR (-25.45%)
-36.92 EUR (-36.92%)
-18.00 EUR (-18.00%)
-71.16 EUR (-71.16%)
About Inventiva SA
Market Capitalization 211.30M
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
| Headquarters (address) |
50 rue de Dijon Daix 21121 France |
| Phone | 33 3 80 44 75 00 |
| Website | https://www.inventivapharma.com |
| Employees | 123 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | IVA |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 1.43 - 4.44 |
| Market Capitalization | 211.30M |
| P/E trailing | -1.01 |
| P/E forward | -1.73 |
| Price/Sale | 10.96 |
| Price/Book | -2.97 |
| Beta | 0.805 |
| EPS | -2.06 |
| EPS France (ID:70, base:331) | 3.06 |